Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Germline EGFR Mutations and Familial Lung Cancer.
Oxnard GR, Chen R, Pharr JC, Koeller DR, Bertram AA, Dahlberg SE, Rainville I, Shane-Carson K, Taylor KA, Sable-Hunt A, Sholl LM, Teerlink CC, Thomas A, Cannon-Albright LA, Fay AP, Ashton-Prolla P, Yang H, Salvatore MM, Addario BJ, Jänne PA, Carbone DP, Wiesner GL, Garber JE. Oxnard GR, et al. Among authors: fay ap. J Clin Oncol. 2023 Dec 1;41(34):5274-5284. doi: 10.1200/JCO.23.01372. Epub 2023 Oct 23. J Clin Oncol. 2023. PMID: 37579253
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Fizazi K, et al. Among authors: fay ap. Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. Nat Med. 2024. PMID: 38049622 Free PMC article. Clinical Trial.
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Azad AA, et al. Among authors: fay ap. Eur J Cancer. 2024 Oct 20;213:115078. doi: 10.1016/j.ejca.2024.115078. Online ahead of print. Eur J Cancer. 2024. PMID: 39486165 Free article.
Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study.
Monteiro FSM, Alencar Junior AM, da Trindade KM, Rebelatto TF, Maluf FC, Gazzola AA, Barrios PM, Bellmunt J, de Jesus RG, Silva GEB, Teixeira Junior AAL, Spiess PE, Fay AP. Monteiro FSM, et al. Among authors: fay ap. Oncologist. 2024 Sep 2:oyae220. doi: 10.1093/oncolo/oyae220. Online ahead of print. Oncologist. 2024. PMID: 39222919 Free article.
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
Souza VC, Monteiro FSM, Maluf FC, Werutsky G, Fabrício VC, Gidekel R, Gandur-Quiroga MN, Freitas MRP, Luz M, Campos-Gomez S, Junior JAR, Bastos DA, Sade JP, da Trindade KM, Mota ACA, Fernandes RC, Ruíz AOB, Pereira E Silva BD, de Oliveira FNG, Cutuli HJ, Nogueira L, Aceituno LFG, Fernandez M, Inman E, Caitano M, Herchenhorn D, Ardila-Salcedo J, Pacheco P, de Jesus RG, Gössling G, Soares A, Fay AP. Souza VC, et al. Among authors: fay ap. Clin Genitourin Cancer. 2024 Oct;22(5):102174. doi: 10.1016/j.clgc.2024.102174. Epub 2024 Jul 25. Clin Genitourin Cancer. 2024. PMID: 39181783
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Agarwal N, et al. Among authors: fay ap. Future Oncol. 2024;20(29):2123-2135. doi: 10.1080/14796694.2024.2362108. Epub 2024 Jul 12. Future Oncol. 2024. PMID: 38995237 Free PMC article. Clinical Trial.
The impact of a breast cancer diagnosis on marital outcomes and factors associated with divorce and separation.
Werutsky G, Lopes M, de Jesus RG, Gazola AA, Pellegrini RA, Rebelatto TF, Freitas LVW, Heck AP, da Silva AF, Rodrigues MF, Gössling G, Giacomazzi J, Rocha MS, Rosa DD, Barrios CH, Cronemberger EH, Queiroz GS, Bines J, Simon SD, Fay AP. Werutsky G, et al. Among authors: fay ap. Rev Bras Ginecol Obstet. 2024 Jun 27;46:e-rbgo60. doi: 10.61622/rbgo/2024rbgo60. eCollection 2024. Rev Bras Ginecol Obstet. 2024. PMID: 38994465 Free PMC article.
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy.
Shore ND, Broder MS, Barata PC, Crispino T, Fay AP, Lloyd J, Mellado B, Matsubara N, Pfanzelter N, Schlack K, Sieber P, Soares A, Dalglish H, Niyazov A, Shaman S, Zielinski MA, Chang J, Agarwal N. Shore ND, et al. Among authors: fay ap. Eur Urol Oncol. 2024 Jun 11:S2588-9311(24)00140-8. doi: 10.1016/j.euo.2024.05.009. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38866640 Free article.
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, Myint ZW, Kucharz J, Molina-Cerrillo J, Santini D, Buttner T, Poprach A, Kopecky J, Zeppellini A, Pichler M, Buchler T, Pichler R, Facchini G, Fay AP, Soares A, Manneh R, Iezzi L, Kuronya Z, Russo A, Bourlon MT, Bhuva D, Ansari J, Kanesvaran R, Grande E, Buti S, Santoni M. Incorvaia L, et al. Among authors: fay ap. Cancer Immunol Immunother. 2024 Jun 4;73(8):142. doi: 10.1007/s00262-024-03719-0. Cancer Immunol Immunother. 2024. PMID: 38832989 Free PMC article.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bisonni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N, Buti S, Porta C, Bellmunt J. Massari F, et al. Among authors: fay ap. Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w. Cancer Immunol Immunother. 2024. PMID: 38634928 Free PMC article.
79 results